A Retrospective Evaluation of Patients with Operable Gastrointestinal Stromal Tumor

INTRODUCTION: In this retrospective study, we aimed to evaluate the clinical and histopathological features and survival rates of patients with localized gastrointestinal stromal tumors (GIST).
METHODS: Between April 2004 and October 2014, 94 patients diagnosed with GIST who were referred to the Department of Medical Oncology, Ankara Numune Education and Research Hospital were retrospectively reviewed. A total of 65 nonmetastatic operable GIST patients were included in the study.
RESULTS: The median age was 53 years (22-78) and most patients were male (male/female: 41/24). The most common localization of tumors were stomach (58.5%), non-gastric gastrointestinal (29.2%), and ekstragastrointestinal (12.3%). According to the AFIP prognostic criteria, 24.6% of patients was located in low risk group, 21.5% in intermediate risk group, and 53.9% in high risk group. Only 33.8% of patients received adjuvant imatinib treatment. While the median overall survival (OS) was not reached, 3 year and 2 year disease free survival (DFS) was 81% and 84% respectively. There was no statistically significant difference neither in 2 year DFS nor in 3 year DFS according to gender, tumor site, tumor size, mitotic count, CD34, AFIP risk group and adjuvant treatment.
DISCUSSION AND CONCLUSION: The median OS was not reached in localized GIST patients who underwent surgery, whereas a high DFS rate was found.

Opere Gastrointestinal Stromal Tümörlü Hastalarýn Retrospektif Deðerlendirmesi

GÝRÝÞ ve AMAÇ: Bu retrospektif çalýþmada amacýmýz lokalize gastrointestinal stromal tümörlü (GÝST) hastalarýn klinik ve histopatolojik özellikleri ile saðkalým oranlarýný deðerlendirmektir.
YÖNTEM ve GEREÇLER: Nisan 2004 - Ekim 2014 tarihleri arasýnda Ankara Numune Eðitim ve Araþtýrma Hastanesi Týbbi Onkoloji Kliniði'ne baþvuran GÝST tanýlý 94 hasta arasýndan opere olmuþ ve taný sýrasýnda metastazý olmayan 65 hastanýn dosya bilgileri kaydedildi.
BULGULAR: Çalýþmaya alýnan 65 hastanýn ortanca yaþý 53 (22-78) olup; çoðunluðu erkekti (erkek/kadýn: 41/24). Tümörlerin yerleþim yeri sýklýk sýrasýna göre mide (%58.5), mide dýþý gastrointestinal (%29.2), ve ekstragastrointestinal (%12.3) olarak belirlendi. AFIP'e göre hastalarýn %24.6'sý düþük, %21.5'i orta ve %53.9’u yüksek risk grubunda yer alýrken; sadece %33.8'i adjuvan imatinib tedavisi aldý. Tüm grupta ortanca genel saðkalýma ulaþýlamazken; 3 yýllýk hastalýksýz saðkalým (DFS) %81, 2 yýllýk DFS ise %84 olarak belirlendi. Cinsiyet, tümörün lokalizasyonu, tümör çapý, mitoz sayýsý, CD34, AFIP risk grubu ve adjuvan tedavi alýp almama durumuna göre hem 2 hem de 3 yýllýk DFS'de istatistiksel anlamlýlýða ulaþan fark saptanmadý.
TARTIÞMA ve SONUÇ: Taný sýrasýnda lokalize olup cerrahi tedavi yapýlan GÝST olgularýnda ortanca saðkalýma ulaþýlamazken; DFS oranlarý yüksek bulunmuþtur.